Anthropic has bought Mithril Medicine, a one-person biotech developing treatments for two rare forms of muscular dystrophy, and is now running drug discovery programs of its own. Anthropic disclosed the deal on October 27 in a research post that also reported early results from Claude-assisted work with six outside drug developers. The purchase price was not disclosed.
Mithril founder Cody Tranbarger used Claude to organize contracts, logistics and experiments with 11 external labs, according to Anthropic. The company says one potential treatment went from an idea to promising results in mice in less than 18 months. Tranbarger now works at Anthropic and is continuing the research, and Anthropic says a drug could be ready for human clinical trials as soon as late 2028 if the results hold.
Mithril was founded about 18 months ago with Atlas Venture, which provided a seed round. It developed bispecific antibodies aimed at LAMA2-related congenital muscular dystrophy and other extracellular matrix diseases, supported by a small group of part-time consultants. Tranbarger, who previously worked in venture capital and crossover investing, calls the approach Pipeline-in-a-Person: one scientist, backed by AI, running several drug programs in parallel.
Key facts
- 01Anthropic acquired Mithril Medicine, a one-person biotech working on two rare forms of muscular dystrophy; the price was not disclosed.
- 02Founder Cody Tranbarger used Claude to coordinate work with 11 external labs, reaching promising mouse results in under 18 months.
- 03Anthropic says a Mithril drug could be ready for human clinical trials as soon as late 2028.
- 04At Enveda, Claude cut human review time on 1,061 pages of manufacturing documents by 89%, from 25+ hours to under 3.
- 05Bristol Myers Squibb plans to expand its Claude-based clinical trial planning work in 2027.
Tranbarger gave three reasons for joining: more resources for Mithril's programs, a chance to learn how many programs one person can run at once, and a platform to spread the model across biopharma. Anthropic says he will start additional programs. Separately, the company has begun its own discovery efforts, including programs for rare childhood forms of muscular dystrophy where Claude handles much of the scientific and operational work.
The partner results made up most of the announcement. At Enveda, Claude reviewed 1,061 pages of manufacturing documentation, caught all 11 issues human reviewers had found and flagged seven more they missed. Human review time fell 89%, from more than 25 hours to under three. Claude also drafted a regulatory document in four hours, a task that takes about three months by hand.
Generate Biomedicines scientists used Claude Code to propose shorter designs for a component of a CAR T-cell therapy. One design was about 70% shorter than the standard version and, in lab tests, let immune cells produce roughly 10 times as many cancer-detecting receptors, kill tumor cells more efficiently and stay active longer.
At Divergence Labs, which works on food allergies, Claude generated roughly 35,000 antibody designs in about a month. Early tests found three binders to IgE and 20 molecules that could dislodge IgE from immune cells, three of which appeared to work better than standard medication. BigHat Biosciences tested about 1,010 Claude-proposed variants over roughly 10 weeks, and the best bound more than 10 times more tightly than the originals.
Bristol Myers Squibb is using Claude to assess plans for an early-stage drug and estimate its odds of success in clinical trials, and the companies plan to expand that work in 2027. Michael Pourdehnad, who heads early clinical development for hematology, oncology and cell therapy at BMS, said the analysis would otherwise have taken days.
“From a single prompt, Claude generated a robust initial analysis”— Michael Pourdehnad, SVP and Head of Early Clinical Development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb
The Column Group is setting up Pleiades, a company intended to run a growing number of complex drug programs with a small team using Claude. Its first Claude skill, built to assess drug targets, was evaluated on 45 target-disease pairs.
Mithril is Anthropic's second life sciences acquisition this year, following its purchase of Coefficient Bio for roughly $400 million. Anthropic has also launched Claude Science, a research workbench, along with Claude credits for life scientists and a Life Sciences Verification Program that gives trusted organizations more permissive safeguards.
Anthropic said the work is early and mostly preclinical, meaning none of the candidates has been tested in humans. The company plans to scale the effort substantially and extend Claude's role into clinical trials as the programs advance.
Working on something we should cover, or seeing a story we missed? Send leads, documents, or feedback to hello@aichatdaily.com. For sensitive tips, see our secure tips page for Signal and PGP options.
Spotted an error? Email hello@aichatdaily.com with the URL and the issue, or read our full corrections policy.
